Acute-on-chronic liver failure
Plasma exchange in ACLF: a real 28-day signal that does not survive to 90 days
A 194-patient randomised trial found that a strategy of five planned sessions of standard-volume therapeutic plasma exchange reduced 28-day mortality by 19.6 percentage points. The difference was no longer evident at 90 days, 42% did not complete all five sessions, and the cohort did not include patients with active infection, haemodynamic instability or respiratory organ failure.
Read Deep Dive